

Index

- actin reorganisation 127
- activator protein-1 161
- acute inflammation 1–12
- adhesion molecule, glomerulonephritis 199, 200
- airway epithelial cell 172, 174
- airway hyperreactivity 165
- airway inflammation 120, 123, 159–179
- airway remodelling 160
- alveolar macrophage 178
- ALXR 121, 122, 128
- angiogenesis 97
- annexin 1 (AnxA1) 124, 128, 148–152, 229
- annexin 1, knockout 148
- annexin 1, peptide 148, 149
- anti-IL-5 mAb 166
- anti-TNF mAb, humanized, *see* infliximab
- antigen (VLA)-4 171
- apoptosis 19–28, 57–68, 75–86, 172, 174, 176, 178, 202
- apoptotic cell, opsonisation of 124
- apoptotic cell clearance 40–47, 119, 207, 208
- apoptotic cell clearance, complement 44
- apoptotic cell clearance, pattern recognition 40
- apoptotic cell death 22–24
- apoptotic cell recognition 124
- apoptotic cell-associated molecular pattern (ACAMP) 40
- arthritis 94
- aspirin 106, 120
- asthma 97, 120, 159, 165, 166
- asthma, cat-allergic 165
- atherosclerotic plaque rupture 120
- ATL 97, 120, 123
- autacoids 96
- basophils 172
- Bax 174
- Bcl-2 174
- Bcl-x 174
- Bcl-xL 174
- bone marrow transplant 97
- bone morphogenic protein-7 208
- braking signal 125
- bronchial epithelium 159
- C1q deficiency 208
- caspase 173, 174
- cathepsin 165
- CD45 173
- CD69 173
- CD95, *see* Fas
- cell-based therapy 212
- cell-cell interaction 95, 106
- chemoattractant 98
- chronic myeloid leukaemia 120
- chronic obstructive pulmonary disease (COPD) 160, 162–164
- ciclesonide 160
- cigarette smoke 160

- cilomilast 164
colitis, *see* inflammatory bowel disease
collectin 46
corticosteroid 162
Crohn's disease 227
CTLA4-Ig 210
cyclin-dependent kinase 212
cyclooxygenase (COX) 98
cyclooxygenase-2 (COX-2), aspirin acetylation of 120
cysteine-cysteine chemokine receptor-3 (CCR3) 172
CCR3 antagonist 172
cysteinyl leukotriene (LT) antagonist 162
cystic fibrosis 97, 120
cytokine 160, 166–170
cytokine, anti-inflammatory 169, 170
cytokine, pro-inflammatory 166–169
cytoskeleton rearrangement 124
- dendritic cell 103, 174
dermal inflammation 97
DHA 107, 108
DNA vaccine 165
drug discovery, anti-inflammatory 1
- eicosanoid 3
endothelial cell 102, 106, 159, 204, 205
eosinophil 159, 171–176
eosinophil apoptosis 21, 22, 172–174
eotaxin 172
EPA 107, 108
15-epi-LX, *see* lipoxin, aspirin-triggered
epithelial cell, apoptotic 178
epithelial mesenchymal trans-differentiation 122
epithelial to mesenchymal transition (EMT) 208
E-selectin 171
E-series, resolvin 95, 96
etanercept 169
eye, LX and ATL actions 97
- Fas (CD95) 173
Fel d 1 165
fibroblast 102, 159, 174
fibronectin 173
fibrosis 160
formyl peptide-receptor like-1 (FPRL-1) 121, 149–151
- gastrointestinal tract 223
glomerular injury, mechanism of 196
glomerulonephritis 97, 119, 120, 198–200, 203, 204, 209–213
glucocorticoid 104, 125, 141–148, 151, 152, 159–161
glucocorticoid, history 142, 143
glucocorticoid, non genomic action 143–145
glucocorticoid, receptor 143–147
GM-CSF 173
Goodpasture's disease 211
granulocyte apoptosis 19–28
granulocyte apoptosis, intracellular mechanism 26, 27
GTPase 127
- Helicobacter pylori* 225
hepatocyte 174
human PMN 100
human vascular endothelial cell 99
hypoallergenic isoforms 165
- IgE 165
IgE inhibitor 170, 171
IL-1 β 198
IL-3 173
IL-4 165, 168, 176, 209, 213
IL-5 173
IL-8 122
IL-9 168, 173
IL-10 165, 169, 209, 210, 213
IL-12 169, 173, 198
IL-13 165, 168, 173, 176
IL-15 173

- immunotherapy, asthma 165, 166
inducible costimulator (ICOS) 210
inflammatory bowel disease (IBD) 97, 123, 223
infliximab 169
interferon (IFN)- α 169
interferon (IFN)- γ 165, 198
interleukin-8 (IL-8) 122
interstitial cell 102
intracellular acidification 25
ischaemia-reperfusion (I/R) injury 97
ischaemic acute renal failure 123
- knockouts 148
- LC-UV-MS/MS 105, 106
leukocyte 99, 103
lipidomic approach 101, 103
lipoxin (LX) 97, 119–123, 125, 225
lipoxin, aspirin-triggered 120
lipoxin A₄ 122, 149, 151
lipoxygenase (LO) 98, 108
LPC 125
LTB 178
LTB₄ 162, 163
luminal entry 176
lymphocyte 197
- macrophage 4, 75–86, 123, 160, 174, 196, 197, 203, 204
macrophage M Φ , glomerulonephritis 203, 204
macrophage apoptosis 76–79
macrophage emigration 79–85
mast cell 159, 172, 176
MCP-3 172
MCP-4 172
Mechnikov 96
mediator, anti-inflammatory 8
mediator antagonist 161–163
mepolizumab 166
mesangial cell proliferation 122
mitochondrial cytochrome C 173
mitochondrial outer membrane permeabilisation (MOMP) 24
monocyte 126, 127
mononuclear cell 173
mouse tissue 107
mucosal epithelia 102
mycophenolate mofetil (MMF) 212
MYH9 128
- natalizumab 171
neutrophil 59, 60, 75, 160, 165, 176, 177, 197
neutrophil apoptosis 19, 20, 22, 172, 176
neutrophil elastase 165
NF- κ B 9, 26, 161, 173
nitric oxide 199
nonsteroidal anti-inflammatory drug (NSAID) 223
nuclear factor of activated T cells (NF-AT) 161
- omalizumab 170
omega-3 polyunsaturated fatty acid (ω -3 PUFA) 93
oxidative stress 177
- P450 106
pathogen-associated molecular pattern (PAMP) 40
pattern recognition receptor (PRR) 40
PRR, prototype CD14 41–43
PD1 108
pentraxin 47
peptide, anti-inflammatory 142, 149
periodontitis 94, 97, 120
peripheral blood neutrophils 98
peritonitis 97
phagocyte 93, 123–125
phagocytic cell 172
phagocytic clearance 174
phagocytosis 59, 85
phosphatidylcholine 125
phosphodiesterase inhibitor 164
phospholipid asymmetry 124

- platelet 102
- platelet-derived growth factor (PDGF) 202
- PMN, human 100
- PMN recruitment 123
- podocyte 204
- probiotics 230
- programmed cell death, *see* neutrophil apoptosis
- prostaglandin (PG) 7, 176
- protease inhibitor 164
- protease-mediated inflammation 177
- protectin 96, 108, 119
- proteinase 3 165
- proteomic approach 101, 103
- ω -3 PUFA 93

- RANTES 172
- receptor tyrosine kinase 122
- recombinant allergen 165
- resolution indices 104
- resolvin 95, 96, 107, 108, 119, 120
- rituximab 212
- RU 24858 161
- RvE₁ 106, 108

- scavenger receptor 43
- secondary necrosis 174
- selectin 171, 177
- siglec-8 173
- smooth muscle cell 159
- STAT-6 168
- stem cell, glomerular 206
- surface receptor 57, 60–64

- T regulatory (Treg) cell 210
- TBC1269 177
- Th2 cell 172
- tissue inhibitor of matrix metalloproteinase (TIMP) 169
- TNF- α 122, 168, 173, 198
- TNF-related apoptosis-inducing ligand (TRAIL) 23, 24
- transcellular biosynthesis 102, 106
- transforming growth factor (TGF)- β 165, 208

- VCAM-1 171
- VEGF 205, 211

The PIR-Series

Progress in Inflammation Research

Homepage: <http://www.birkhauser.ch>

Up-to-date information on the latest developments in the pathology, mechanisms and therapy of inflammatory disease are provided in this monograph series. Areas covered include vascular responses, skin inflammation, pain, neuroinflammation, arthritis cartilage and bone, airways inflammation and asthma, allergy, cytokines and inflammatory mediators, cell signaling, and recent advances in drug therapy. Each volume is edited by acknowledged experts providing succinct overviews on specific topics intended to inform and explain. The series is of interest to academic and industrial biomedical researchers, drug development personnel and rheumatologists, allergists, pathologists, dermatologists and other clinicians requiring regular scientific updates.

Available volumes:

- T Cells in Arthritis*, P. Miossec, W. van den Berg, G. Firestein (Editors), 1998
Chemokines and Skin, E. Kownatzki, J. Norgauer (Editors), 1998
Medicinal Fatty Acids, J. Kremer (Editor), 1998
Inducible Enzymes in the Inflammatory Response,
D.A. Willoughby, A. Tomlinson (Editors), 1999
Cytokines in Severe Sepsis and Septic Shock, H. Redl, G. Schlag (Editors), 1999
Fatty Acids and Inflammatory Skin Diseases, J.-M. Schröder (Editor), 1999
Immunomodulatory Agents from Plants, H. Wagner (Editor), 1999
Cytokines and Pain, L. Watkins, S. Maier (Editors), 1999
In Vivo Models of Inflammation, D. Morgan, L. Marshall (Editors), 1999
Pain and Neurogenic Inflammation, S.D. Brain, P. Moore (Editors), 1999
Anti-Inflammatory Drugs in Asthma, A.P. Sampson, M.K. Church (Editors), 1999
Novel Inhibitors of Leukotrienes, G. Folco, B. Samuelsson, R.C. Murphy (Editors), 1999
Vascular Adhesion Molecules and Inflammation, J.D. Pearson (Editor), 1999
Metalloproteinases as Targets for Anti-Inflammatory Drugs,
K.M.K. Bottomley, D. Bradshaw, J.S. Nixon (Editors), 1999
Free Radicals and Inflammation, P.G. Winyard, D.R. Blake, C.H. Evans (Editors), 1999
Gene Therapy in Inflammatory Diseases, C.H. Evans, P. Robbins (Editors), 2000
New Cytokines as Potential Drugs, S. K. Narula, R. Coffmann (Editors), 2000
High Throughput Screening for Novel Anti-inflammatories, M. Kahn (Editor), 2000
Immunology and Drug Therapy of Atopic Skin Diseases,
C.A.F. Bruijnzeel-Komen, E.F. Knol (Editors), 2000
Novel Cytokine Inhibitors, G.A. Higgs, B. Henderson (Editors), 2000
Inflammatory Processes. Molecular Mechanisms and Therapeutic Opportunities,
L.G. Letts, D.W. Morgan (Editors), 2000
Cellular Mechanisms in Airways Inflammation, C. Page, K. Banner, D. Spina (Editors), 2000
Inflammatory and Infectious Basis of Atherosclerosis, J.L. Mehta (Editor), 2001
Muscarinic Receptors in Airways Diseases, J. Zaagsma, H. Meurs, A.F. Roffel (Editors), 2001
TGF- β and Related Cytokines in Inflammation, S.N. Breit, S. Wahl (Editors), 2001

Nitric Oxide and Inflammation, D. Salvemini, T.R. Billiar, Y. Vodovotz (Editors), 2001

Neuroinflammatory Mechanisms in Alzheimer's Disease. Basic and Clinical Research, J. Rogers (Editor), 2001

Disease-modifying Therapy in Vasculitides, C.G.M. Kallenberg, J.W. Cohen Tervaert (Editors), 2001

Inflammation and Stroke, G.Z. Feuerstein (Editor), 2001

NMDA Antagonists as Potential Analgesic Drugs, D.J.S. Sirinathsinghji, R.G. Hill (Editors), 2002

Migraine: A Neuroinflammatory Disease? E.L.H. Spierings, M. Sanchez del Rio (Editors), 2002

Mechanisms and Mediators of Neuropathic pain, A.B. Malmberg, S.R. Chaplan (Editors), 2002

Bone Morphogenetic Proteins. From Laboratory to Clinical Practice, S. Vukicevic, K.T. Sampath (Editors), 2002

The Hereditary Basis of Allergic Diseases, J. Holloway, S. Holgate (Editors), 2002

Inflammation and Cardiac Diseases, G.Z. Feuerstein, P. Libby, D.L. Mann (Editors), 2003

Mind over Matter – Regulation of Peripheral Inflammation by the CNS, M. Schäfer, C. Stein (Editors), 2003

Heat Shock Proteins and Inflammation, W. van Eden (Editor), 2003

Pharmacotherapy of Gastrointestinal Inflammation, A. Guglietta (Editor), 2004

Arachidonate Remodeling and Inflammation, A.N. Fonteh, R.L. Wykle (Editors), 2004

Recent Advances in Pathophysiology of COPD, P.J. Barnes, T.T. Hansel (Editors), 2004

Cytokines and Joint Injury, W.B. van den Berg, P. Miossec (Editors), 2004

Cancer and Inflammation, D.W. Morgan, U. Forssmann, M.T. Nakada (Editors), 2004

Bone Morphogenetic Proteins: Bone Regeneration and Beyond, S. Vukicevic, K.T. Sampath (Editors), 2004

Antibiotics as Anti-Inflammatory and Immunomodulatory Agents, B.K. Rubin, J. Tamaoki (Editors), 2005

Antirheumatic Therapy: Actions and Outcomes, R.O. Day, D.E. Furst, P.L.C.M. van Riel, B. Bresnihan (Editors), 2005

Regulatory T-Cells in Inflammation, L. Taams, A.N. Akbar, M.H.M. Wauben (Editors), 2005

Sodium Channels, Pain, and Analgesia, K. Coward, M. Baker (Editors), 2005

Turning up the Heat on Pain: TRPV1 Receptors in Pain and Inflammation, A.B. Malmberg, K.R. Bley (Editors), 2005

The NPY Family of Peptides in Immune Disorders, Inflammation, Angiogenesis and Cancer, Z. Zukowska, G. Z. Feuerstein (Editors), 2005

Toll-like Receptors in Inflammation, L.A.J. O'Neill, E. Brint (Editors), 2005

Complement and Kidney Disease, P. F. Zipfel (Editor), 2006

Chemokine Biology – Basic Research and Clinical Application, Volume 1: Immunobiology of Chemokines, B. Moser, G. L. Letts, K. Neote (Editors), 2006

The Hereditary Basis of Rheumatic Diseases, R. Holmdahl (Editor), 2006

Lymphocyte Trafficking in Health and Disease, R. Badolato, S. Sozzani (Editors), 2006

In Vivo Models of Inflammation, 2nd Edition, Volume I, C.S. Stevenson, L.A. Marshall, D.W. Morgan (Editors), 2006

In Vivo Models of Inflammation, 2nd Edition, Volume II, C.S. Stevenson, L.A. Marshall, D.W. Morgan (Editors), 2006

Chemokine Biology – Basic Research and Clinical Application. Volume II: Pathophysiology of Chemokines, K. Neote, G.L. Letts, B. Moser (Editors), 2007

Adhesion Molecules: Function and Inhibition, K. Ley (Editor), 2007

The Immune Synapse as a Novel Target for Therapy, L. Graca (Editor), 2008